Feng Lu

Title: The Innovations of Feng Lu

Introduction

Feng Lu is a notable inventor based in Kunming, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of glycosaminoglycan derivatives. With a total of 2 patents to his name, his work focuses on innovative solutions for thrombotic diseases.

Latest Patents

Feng Lu's latest patents include the following:

1. **Fuc3S4S substituted oligoglycosaminoglycan and preparation method thereof** - This patent discloses a Fuc3S4S substituted oligoglycosaminoglycan with a weight-average molecular weight (Mw) of about 4.5-9 kD. It includes a pharmaceutical composition containing this oligoglycosaminoglycan, a preparation method, and its use in preparing medicines for preventing and/or treating thrombotic diseases.

2. **Low molecular weight glycosaminoglycan derivative, pharmaceutical composition thereof, preparation method therefor and use thereof** - This patent provides a low-molecular-weight fucosylated glycosaminoglycan derivative (dLFG) that exhibits anticoagulant activity. It details a preparation method, a pharmaceutical composition comprising dLFG or a pharmaceutically acceptable salt thereof, and the use of dLFG and its pharmaceutical composition in preparing medicine for treating thrombotic diseases.

Career Highlights

Feng Lu has worked with prominent companies in the pharmaceutical industry, including Jiuzhitang Co., Ltd. and Hainan Jiuzhitang Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative pharmaceutical solutions.

Collaborations

Feng Lu has collaborated with notable colleagues such as Jinhua Zhao and Jikai Liu. These partnerships have likely enhanced his research and development efforts in the field of glycosaminoglycans.

Conclusion

Feng Lu's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to advancing medical science. His work in developing glycosaminoglycan derivatives is paving the way for new treatments for thrombotic diseases.